DE60334316D1 - Frpb proteinmutante und verfahren zur erneuten faltung - Google Patents

Frpb proteinmutante und verfahren zur erneuten faltung

Info

Publication number
DE60334316D1
DE60334316D1 DE60334316T DE60334316T DE60334316D1 DE 60334316 D1 DE60334316 D1 DE 60334316D1 DE 60334316 T DE60334316 T DE 60334316T DE 60334316 T DE60334316 T DE 60334316T DE 60334316 D1 DE60334316 D1 DE 60334316D1
Authority
DE
Germany
Prior art keywords
frpb protein
removal procedure
protein mutant
frpb
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334316T
Other languages
German (de)
English (en)
Inventor
Ralph Biemans
Philippe Denoel
Christiane Feron
Carine Goraj
Jeroen Kortekaas
Jan Poolman
Jan Tommassen
Vincent Weynants
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
TECHNOLOGY FOUNDATION STICHTIN
Universiteit Utrecht
Original Assignee
GlaxoSmithKline Biologicals SA
TECHNOLOGY FOUNDATION STICHTIN
Rijksuniversiteit Utrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA, TECHNOLOGY FOUNDATION STICHTIN, Rijksuniversiteit Utrecht filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of DE60334316D1 publication Critical patent/DE60334316D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60334316T 2002-08-30 2003-08-28 Frpb proteinmutante und verfahren zur erneuten faltung Expired - Lifetime DE60334316D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
PCT/EP2003/009634 WO2004020463A2 (en) 2002-08-30 2003-08-28 Mutant protein and refolding method

Publications (1)

Publication Number Publication Date
DE60334316D1 true DE60334316D1 (de) 2010-11-04

Family

ID=9943242

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334316T Expired - Lifetime DE60334316D1 (de) 2002-08-30 2003-08-28 Frpb proteinmutante und verfahren zur erneuten faltung

Country Status (10)

Country Link
US (1) US20060141563A1 (cg-RX-API-DMAC7.html)
EP (1) EP1572729B1 (cg-RX-API-DMAC7.html)
JP (1) JP2006516183A (cg-RX-API-DMAC7.html)
AT (1) ATE481983T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003287945A1 (cg-RX-API-DMAC7.html)
CA (1) CA2495086A1 (cg-RX-API-DMAC7.html)
DE (1) DE60334316D1 (cg-RX-API-DMAC7.html)
ES (1) ES2351598T3 (cg-RX-API-DMAC7.html)
GB (1) GB0220199D0 (cg-RX-API-DMAC7.html)
WO (1) WO2004020463A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414667A (en) * 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
CA2654706A1 (en) * 2006-06-12 2007-12-21 Nathalie Devos Neisseria meningitidis lipooligosaccharide vaccine
JP5568017B2 (ja) * 2008-12-25 2014-08-06 一般財団法人化学及血清療法研究所 組換え鶏伝染性コリーザワクチン及びその製造方法
US9259462B2 (en) * 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
CA2811699C (en) * 2010-09-28 2019-07-02 Abera Bioscience Ab Fusion protein for secretory protein expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265567B1 (en) * 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
DE69636739T2 (de) * 1995-12-21 2007-10-18 Ajinomoto Co., Inc. Verfahren zur rückfaltung von menschlichem activin a
NZ520445A (en) * 2000-01-25 2004-02-27 Univ Queensland Proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA

Also Published As

Publication number Publication date
AU2003287945A8 (en) 2004-03-19
JP2006516183A (ja) 2006-06-29
US20060141563A1 (en) 2006-06-29
EP1572729A2 (en) 2005-09-14
WO2004020463A3 (en) 2005-08-18
WO2004020463A2 (en) 2004-03-11
GB0220199D0 (en) 2002-10-09
ES2351598T3 (es) 2011-02-08
ATE481983T1 (de) 2010-10-15
AU2003287945A1 (en) 2004-03-19
EP1572729B1 (en) 2010-09-22
CA2495086A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
EP2444809A3 (en) Methods of generating and screening for proteases with altered specificity
DE60332024D1 (de) Verfahren zur herstellung von soja protein
EP1490677A4 (en) COMPUTER METHOD FOR DESIGNING ENZYMES FOR THE INCORPORATION OF AMINO ACID ANALOGUES INTO PROTEINS
DE60330376D1 (de) Defructosylierungsverfahren
DE60309087D1 (de) System und Methode zur Reglung von optischen Verstärkern
DE602004023229D1 (de) Mais metallothionen promoter 2 und methoden zur verwendung
SG149000A1 (en) Gag binding proteins
DE69932845D1 (de) Methoden zur quantifizierung von hla-dr und cd11b
EP1482858A4 (en) PROCESS FOR THE REPARATION OF ANEURYSMS
ATE302844T1 (de) Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms
DE60307617D1 (de) Verfahren zur gewinnung von gold
DE60334316D1 (de) Frpb proteinmutante und verfahren zur erneuten faltung
ATE492631T1 (de) Verwendung von mutationen zur verbesserung von aspergillus-phytasen
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE60301283D1 (de) Verfahren zur Bestimmung von Biopolymeren
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATA19172002A (de) Verfahren zum einbringen und verblasen von gesteinsstaub sowie vorrichtung zur durchführung dieses verfahrens
NO20050599L (no) Fremgangsmate for a anrike og spore patologisk modifiserte prion-proteiner (PRPsc)
DE60336205D1 (de) Verfahren zur Betriebsmodusnotifizierung.
ATE274599T1 (de) Verfahren zur enzymatischen racematspaltung von aminomethyl-aryl-cyclohexanol-derivaten
DE60215206D1 (de) Enzymatisches verfahren zur enantiomeren trennung von aminosäuren
DE60317620D1 (de) Methode zur Bestimmung von UDP-GlcNac
DE50309626D1 (de) Verfahren zur vorhersage der expressionseffizienz in zellfreien expressionssystemen
ATE451457T1 (de) Verfahren zur dipeptidherstellung
DE602004022323D1 (de) Tyrosinasemutante und verfahren zur verwendung davon